SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

SION

Sionna Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed6d 18h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The Phase 2 AscenSION CF trial initiation in Q1 2027 is the key near-term catalyst. Monitor enrollment and any early efficacy signals (sweat chloride reduction) from the 28-day study. The cash runway into H2 2029 reduces near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

SION drug pipeline →

SION-2222

● Neutral Named in this press release
Impact
Phase
Phase 2a (scheduled to initiate Q1 2027); Phase 1 completed
Time to market
At least 3 to 5 years away. The dual combination enters Phase 2a in Q1 2027; a successful Phase 2a and subsequent Phase 3 program plus FDA review would be needed before any approval.
Next catalyst
None dated

What to watchThe next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$3.70
T+0 close · Nov 10, 2026 · via day close
Latest settled
0.00%
T+1 · $3.70
Vs SPY
−1.32%
α at T+1
Next horizon
T+5
in 6h
  1. T+0 · Nov 10 $3.70entry
  2. T+1 · 6d ago 0.00%α −1.32% · $3.70
  3. T+4 · todayOpen
  4. T+5 · in 6h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sionna reported a Q3 2026 net loss of $32.4M ($0.72 per share), wider than the $20.3M loss a year ago, and ended the quarter with $249.8M in cash. The company announced a 46% workforce reduction and plans to initiate a Phase 2 proof-of-concept trial for its lead dual combination SION-451 + SION-2222 in Q1 2027, after the SION-719 add-on trial failed to meet its endpoint.

Key Financial Metrics

EPS
−$0.72
Revenue
$0.00
est $0.00

Key Facts

  • Net loss of $32.4M for Q3 2026, compared to $20.3M in Q3 2025
  • Net loss per share of $0.72, compared to $0.46 in the year-ago quarter
  • Cash, cash equivalents and marketable securities of $249.8M as of September 30, 2026
  • Workforce reduction of approximately 46% implemented in September 2026
  • SION-451 + SION-2222 dual combination advancing to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in Q1 2027
  • PreciSION CF Phase 2a trial of SION-719 did not achieve its key activity endpoint; SION-719 not advancing as add-on to standard of care
  • Cash runway expected to fund operations into the second half of 2029

Financial Impact

Net loss widened by $12.1M YoY; cash burn of $60.5M in the nine months ended September 30, 2026; workforce reduction expected to reduce operating expenses

net losscash positionoperating expenses

Risk Factors

  • SION-451 + SION-2222 is still in early-stage development; Phase 2 results may not replicate preclinical or Phase 1 data
  • Failure of SION-719 as add-on to Trikafta raises questions about NBD1 stabilization approach in combination with existing therapies
  • Workforce reduction may impact morale and ability to execute on pipeline
  • Competition from Vertex's Trikafta and other CFTR modulators

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
35% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399301

Track record

22 reports on SION

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 5/10 Viewing Entry $3.70 Now $3.12 −15.68% settles Nov 17
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
  5. Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
  6. Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
  7. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
  8. Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
  9. Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
  10. Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 8h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026